Albert. Labs

CSE: ABRT

Fully-integrated biopharmaceutical company, bringing innovative prescription medicines to patients with unmet mental health needs

Corporate Presentation - January 2023

Albert Labs Mission

Albert Labs is a **pharmaceutical** focused, natural drug development company using an **accelerated UK & US regulatory pathway** to deliver faster access to novel **mental health therapies** for patients with **unmet needs**

Public Listings:

CSE CANADIAN® SECURITIES EXCHANGE
The Exchange For Entrepreneurs

“ABRT”

BÖRSE FRANKFURT

“VB50”

Partnerships:

The Christie NHS FOUNDATION TRUST

MANCHESTER 1824
The University of Manchester

NGENŪ CRO

NCRI Advancing Cancer Research Together

Albert Labs Overview

1

A huge global market
Developing pharmaceuticals for a **growing global market of 1 billion anxiety & depression sufferers**

2

Lower cost & faster pathways
Differentiated strategy

- **speed to market** - delivering effective medicines with a good safety profile
- **lower cost** - grant funding, 45% rebate from Australian Government on first-in-human study
- **proprietary cultivation technology** - patented bioreactor growth for psilocybin

3

Delivering shareholder value
Outstanding opportunity for returns to shareholders

- route to early market approval
- early revenues & profits
- growth pathways to global markets
- attractive valuation compared to peers

- Facilities in Canada, Portugal & UK
- First molecule KRN-101
- First-in-human trial Q2 2023
- Health Canada License & approved SAP provider

Accelerated Strategy to Revenue & Profit

Treatments that have already shown to be clinically effective with positive safety profiles

Regulatory pathway with early reimbursement in the UK, and swift expansion to US

Cancer related distress accelerates regulatory approval and access to other multi-billion markets

Patent protected manufacturing and opportunities for extensive data protection

Experienced management team & expert advisory boards

Pre-clinical trials underway in readiness for clinical trial start in Q1 2023

Addressing Mental Health

Albert Labs' initial focus is cancer-related anxiety in the UK - Why?

Mental health conditions remain the single largest cause of disability worldwide[1]

Antidepressants are over **35 years old**[2], relatively **ineffective** and can come with **severe side effects**

17%

of the UK[3] population are now prescribed a mental health medicine each year

Accelerated product development cycle - with reduced regulatory risk

Large unmet need - **1 million patients with 50-100K new sufferers each year**[4]

£7.5b Total Available UK Market - High potential revenue ~ £7.5k per treatment

1)Department of Health, 2011 2) D Wong et al., 1995 3) Public Health England, 2018 4) J Walker et al., 2014

About Us

Management Team

Dr Michael Raymont
Chief Executive Officer

Well seasoned leader in venture capital & healthcare investment. **Previously held a senior government positions**, President of the National Research Council, where he led >$1bn of R&D and technology commercialization programs for the govt of Canada.

Dr Malcolm Barratt-Johnson
Chief Medical Officer

25+ years as a Clinical & Regulatory Strategist. **A former Licensing and Clinical Trials Assessor at the UK Government's Medicines & Healthcare products Regulatory Agency (MHRA)**. Also chaired the European Commission's Advisory Board in Innovative Research.

Santoke Naal
Chief Operating Officer

25+ years of experience in executive management, brand building and retail distribution in the European pharmaceutical markets, working with Novartis and Bristol Myers. **Previous managing director for Pierre Fabre a natural extracts for prescription medicines specialist.**

Professor Sara Tai, MSc, D.ClinPsy, CPsychol
Principal Lead

Prof. Tai is a Senior Lecturer in Clinical Psychology at the University of Manchester, has extensive clinical research experience, having **developed psychological interventions for a variety of mental health disorders such as depression,** psychosis and bipolar.

Ali Gulamhusein, P.Eng
Chief Development Officer

15+ years of engineering experience developing and commercialising novel process technologies in, electrochemistry and the pharmaceutical sector. **Focused on the design and build of systems for commercial pharmaceutical production.**

Chand Jagpal
Chief Financial Officer

20+ years in the medical cannabis, agriculture & biotech industries. Previously, CEO of Grand Peak Capital Corp.: a publicly listed venture fund investing in natural resource and technology companies. Chand specialising in Financial Disclosure and Compliance.

Board

Dr Michael Raymont
Chairman

Well seasoned leader in venture capital & healthcare investment. **Previously held a senior government positions**, President of the National Research Council, where he led >$1bn of R&D and technology commercialization programs for the govt of Canada.

Chand Jagpal
Director

20+ years in the medical cannabis, agriculture & biotech industries. Previously, CEO of Grand Peak Capital Corp.: a publicly listed venture fund investing in natural resource and technology companies. Chand specialising in Financial Disclosure and Compliance.

Katie Shelton-Innes
Non Executive Director

A history of **investment banking, raising funds and advising on corporate growth strategy**. She has extensive knowledge in UK financial regulatory compliance and disclosure.

Mike Thompson MBE
Non Executive Director

25+ years in the Public Health, serving as **CEO at The Association of the British Pharmaceutical Industry (ABPI)**, and in senior roles at GSK and Unilever. His service to the biotech, pharma industry and wider life sciences, led to an **MBE in 2021.**

Robert Kang
Director

Spent **15 years as the Director of Listings for the TSX Venture Exchange**. Rob also has extensive knowledge in, policies, regulatory compliance and risk mitigation.

Advisors

Prof. Jo Neill

BSc Pharmacology, PhD in Psychopharmacology

Dr Neill is the Professor of Psychopharmacology at the University of Manchester. She has been researching psychopharmacology for almost 30 years and has **authored over 70 peer-reviewed publications in top scientific journals.**

Prof. Sam Ahmedzai

FRCPGlas, FRCP, FRCPE

Professor Sam Ahmedzai is the **NIHR National Specialty Lead for Cancer**: Supportive Care and Community-Based Research. Also he is the **Chair of the National Cancer Research Institute (NCRI)** Supportive and Palliative Care Clinical Studies Group.

Prof. Saoirse O'Sullivan

BA Mod Hons, PhD

Saoirse is a Professor of Pharmacology at the University of Nottingham. Dr O'Sullivan is **a leading researcher in the field of cannabinoid research & natural psychedelic compounds.**

Prof. Robert Britton

BSc, PhD in Biological and Medicinal Chemistry

A PhD in natural product isolation, structural elucidation and total synthesis, Professor Britton has broad research interests, including natural product drug discovery, **medicinal chemistry & synthesizing structurally complex natural products.**

Dr. Sara Tookey

DClinPsy, PhD, MA, HCPC

Sara is a Clinical Psychologist and an experienced qualitative researcher. **Sara also holds a PhD in Psychology with a specialism in Psycho-oncology, a doctorate in Clinical Psychology, an MA in Existential Phenomenological Psychology.**

Dr. Ricardo Jorge Dinis-Oliveira

PhD, European PhD, DSc

An expert Toxicologist and Pharmacologist. Dr. Dinis-Oliveira is well-published, having authored more than 170 published peer reviewed articles. **In 2021 he was included in the world's top 2% of Scientists, which ranks the most highly cited scientists globally.**

End to End Global Supply Chain & Operations

Manchester, UK

- Clinical Trial sites
- Future Pharmaceutical Manufacture
  - Home Office Licence
  - MHRA Compliant EU GMP

Vancouver, Canada

- Production Scale-up R&D
- Health Canada Licence

Porto, Portugal

- Clinical Trial Manufacture
  - API Production
- CRO Partner Prados Embalados
  - Preclinical & Toxicology
- Infarmed Schedule 1 Licence
- GLP Lab
- Extend RWE trial into the EU Market

Melbourne, Australia

- CRO Partner iNGENu
- Phase 1 Clinical Trial sites
- Clinical Scientists, Biostatisticians, medical and pharmacokinetic experts

Series A - Progress and Use of Funds

Critical milestones

CAD$4.7 million in proceeds raised in two tranches between November 2020 - March 2022

Psilocybin Strategy

Background

Psilocybin is a **Serotonin 5HT$_{2a}$ receptor agonist** which acts on the brain's serotonin system, and **induces neuroplasticity and heightened interconnectivity across the brain**

Recognized by Medical Regulators:

The FDA has granted two breakthrough therapy designations for psilocybin

Medicines & Healthcare products Regulatory Agency

The MHRA has granted two Innovation Passports for psychedelic therapy

Global brain Connectivity [5]:





5) Carhart-Harris, et al., 2012

Psilocybin Treatment & Research

Psilocybin is well tolerated and has a very low potential for abuse

Drug harms in the UK: multicriteria decision analysis, D Nutt et al. 2010



Treatment Protocol

Pre Study — Screening

Week 1 — Medicals and Preparation

Week 2 — Treatment sessions

Week 10 — **Integration Therapy** Follow-up therapy sessions; **Ongoing Care** Digital platform for ongoing data collection, support and education

64 clinical trials to date, using psilocybin as an intervention[7]

Trial status	Number of studies	Number of patients
Completed	21	943
Active	14	547
Recruiting	10	207
KRN-101	1	200

Depression PTSD **Anxiety**
OCD Migraines **Alcoholism**
Anorexia Alzheimer's TBI

Leading Academic Institutes now have dedicated Psychedelic Research Centres:

Imperial College London

Johns Hopkins Center for Psychedelic & Consciousness Research

King's College London

Harvard Medical School

Berkeley University of California

6) D Nutt et al. 2010 7)Clinicaltirals.gov, 01/06/22

Success for Depression & Anxiety - Why Cancer?

1) Reduced regulatory risk
2) Greater efficacy potential
3) Pre-licence Early Access Programmes
4) Label expansion

COMPASS
Navigating Mental Health Pathways

(NASDAQ: CMPS) - Valuation CAD $482m [11/01/2023]

Results from the largest ever study of psilocybin therapy for **treatment-resistant depression** [8] - 2021

- **233 patients**
- Single 25mg dose of psilocybin
- **~25%** of participants showing highly statistically significant reduction in depressive symptoms
- Lasting up to **12 weeks**

JOHNS HOPKINS
SCHOOL of MEDICINE

Established clinical trial success, patients showed major reductions in **cancer related distress** [9] - 2016

- **51 patients**
- Single high dose of psilocybin
- **78% and 83%** of participants showed statistically significant reduction in depression and anxiety symptoms at the **6 months** interval

8) Compass Pathways, 2021 9) S Ross, et al., 2016

Strategy to Value and Revenue

Global Market Access Programme

Q1 2023 →	Q2 2023 →	Q4 2023 →	2024
Preclinical Toxicology	**PK - Clinical Pharmacology**	**RWE Study & Opening of IND**	**Study Expansion**
Porto, Portugal	Melbourne, Australia	Manchester, UK; USA	Worldwide
Animal safety assessment of KRN-101	*Phase 1 In-Human safety study*	*Efficacy study of KRN-101 in targeted indications*	*Expansion of KRN-101 research into further regulatory jurisdictions*
Clinical Trial Application (CTA) Submission	**KRN-101 available for late stage clinical trials in any global jurisdiction** **Ethics approval and study complete** **ILAP-submission and IND-progression**	**Commence Phase 2b RWE Cancer-related distress (MHRA)** **Agree Specials Reimbursement** **Progression towards an FDA clinical program focused on the US Market**	**Phase 3 clinical trials across global jurisdictions** **Licensed Medicine**

Funded through this financing round

PK Study - Australia

1

Assessing the **pharmacokinetic profile of KRN-101**:

- **n = 32**
- **Q2 2023**
- **Duration: ~12 weeks**
- **KRN-101 available for late-stage clinical trials**
- **43.5% reimbursement**
  from Australian Government

NGENŪ CRO

- CRO specialising in clinical trials for psychedelic pharmaceuticals
- Internationally accepted clinical data - meeting the MHRA, EMA, FDA & TGA regulatory requirements.
- Initiation of accelerated 505(b)(2) FDA regulatory pathway including support for pre-IND and IND meetings

RWE Study UK
Cancer related distress

2

Efficacy of KRN-101

Phase 2b trial in patients with Cancer Related Distress

- **Q4 2023**
- **n=200 participants**
- Dose Level: Determined from PK outputs, (~25mg)
- 1mg (Active control)

ILAP - A new UK licensing pathway

To accelerate access and reduce the time to market for patients with urgent & unmet needs

Lead Trial Center

The Christie is the largest single site cancer centre in Europe[10], treating:

- 60,000 cancer patients / year
- Exclusive mental health services for oncology patients

The Christie NHS FOUNDATION TRUST

Real World Evidence is recognised to expedite market authorisation

Pfizer & Merck's Bavencio used Real World Data as part of the original marketing application. Now approved in 38 countries with sales >$800m/yr [11]

MERCK

Pfizer

10) B Feinberg, 2020 11) Clinical Oncology, 2018

Expansion to America

3

Preparation for Investigational New Drug (IND) Application - FDA

- Pre-IND Application in Q4 2023
- Establish clinical trial partners
- Pre-IND Consultation Program
- Identify lead target indication

Possible Label Expansion	US Patients*
☐ PTSD	13 million [12]
☐ Alcohol use disorder	22 million [13]
☐ Generalised Anxiety	9 million [14]

Centralised reimbursement and payer negotiations

Largest pharmaceutical market worldwide - 49.1% for 2021



12) Anxiety & Depression Association of America, 2003 13) Alcohol.org 2019 14) National Institute of Mental Health, 2020

Why RWE? - Quicker & Cost-effective Commercialisation

Randomised Controlled Trials

5-12 Years & significant cost

Preclinical | RCT's | Registered Medicine

Safety & Stability | MHRA Trial Approval | Phase 1 | Phase 2 | Phase 3 | Data Submission (MHRA & EMA) | Authorised Medicine

Healthy Volunteers — Treating Patient Needs

Commercial

Real World Evidence

1-3 Years & cost effective

Preclinical | Real World Evidence | Registered Medicine

Safety & Stability | Trial Approval | PK Study | Phase 2b | Cohort Expansion | Data Submission (MHRA & FDA) | Authorised Medicine

ILAP & accelerated patient recruitment

Specials Reimbursement | Commercial

- Faster
- Lower Risk
- Early revenues
- Lower capital requirements

Early revenues through distribution of KRN as an unlicensed Special

Why the UK for late-stage trials?

1. Unique and rigorous regulatory pathway with early reimbursement
2. Fast market expansion to FDA & EMA
3. Strong government and patient support for psilocybin
4. Growing community of world class companies
5. World class UK research institutions





COMPASS Navigating Mental Health Pathways

Awakn Life Sciences Corp

Small Pharma

Beckley Psytech

Albert. CSE: ABRT Labs

KING'S College LONDON

Imperial College London

MANCHESTER 1824 The University of Manchester

Drug Pipeline Development

Focus on natural, risk-mitigated compounds with a history of safe & efficacious use

Near Term

Psilocybin -KRN-101

Cancer-related distress; anxiety, depression & existential crisis

Mid Term

Multiple Indications

General Anxiety
Major Depression
Addiction
Alzheimer's
Pain

Long Term

Other Tryptamine Compounds

Aeruginascin,
4-Acetoxy-DMT
Psilacetin
5-MeO-DMT
Ibogaine
Kratom

Other Indications:



*Statistics of patients suffering in the UK

15) House of Commons, 2021 16) N Fineberg, 2013 17) Alzheimer's Society, 2019 18)Public Health England, 2020

Operational Strategy

Late stage trials supported by a global footprint



Natural Psilocybin Mycelium

Enabling scale; Proven safe; Preferred by patients.

Other natural sourced potential medicines also being investigated.

First Target KRN-101:

R&D for KRN API Production

API Bioreactor



Formulation



Finished Product

API Bioreactor, IP Protected

Provisional Patent Submitted to United States Patent Office

Consistent, scalable and cost effective production

Additional patent strategy for API medical use cases



Unpublished United States Patent Application
No. 63/236,360 Page 1

METHOD AND SYSTEM FOR CULTURING FUNGI

FIELD

[0001] The present disclosure relates to a method and system for culturing fungi.

BACKGROUND

[0002] Fungi have been propagated in liquid culture. When fungi are propagated in the liquid culture, fluid flow provides and distributes oxygen, nutrients and other important inputs to and throughout the liquid culture. The fluid flow also eliminates CO_2 and other waste products from the liquid culture. Propagation of fungi is facilitated by greater fluid flow. Fluid flow results in shear forces, and shear forces of a sufficient magnitude may damage mycelia or other fungal material.

250L
Liquid Culture

10 days

1,000 Doses
25mg / dose

Cost to produce 1000 doses of KRN-101 = £350k

VS

Estimated market value of 1,000 doses = £1.12m

*Based on Cayman Chemical synthetic psilocybin

Increased:

- Cultivation speed
- Production capability
- Control over variables
- Consistency for medicines
- Synergistic bioactives

Decreased:

- Risk of contamination
- Human intervention
- Cost of production

Further Protection and Exclusivity

Completion of a successful pivotal study could result in data and market exclusivity for **8-11 years in the UK and EU**, and **5-7.5 years data exclusivity in the US**

1

Methods of treatment

A Transdiagnostic approach and framework that maximises KRN-101's penetration into the market and expansion into further indications

2

Novel formulations

Backed up by IND-enabling preclinical data. Addition of monoamine oxidase inhibitors as well as other natural tryptamines that work synergistically

3

Additional manufacturing processes

Improving the capability of other prolific bioactives. Increase production scale of other tryptamine producing sources

*The majority of psychedelic compounds currently pursued are **not patentable** in their own right.



A unique asset that will ensure **market protection** and **speed to commercialisation**

Psychotherapy in combination with KRN-101

KRN and combinational Psychological support is a new care pathway for mental health treatment

At approval Albert Labs' tech-supported care program will be adopted with all necessary training and quality management procedures

- Psychological support from trained healthcare professionals
- Comprehensive training led by Professor Sara Tai, a leading expert in cognitive behaviour
- A comprehensive framework creating the gold standard in terms of reproducibility and quality of care

Albert Labs Care Program (ALCP)

KRN-101 + Psychological support

Therapy at the cutting edge of neuroscience, psychotherapy, psychopharmacology and technology

Operational Strategy

Timeline

Develop and trial KRN-101 to address cancer-related anxiety and depression

PK Study - Tolerability & Safety

Randomized, double-blind, placebo-controlled, Phase 2b trial in patients with Cancer Related Distress

32 participants

- Dose level: 1mg >> 10mg >> 25mg >> 30mg
- 6 Active & 2 Controls per level

Study Development

Design RWE protocol, secure trial registration and ethical sign off

KRN API Ready for Distribution

Production and distribution of KRN API ready for drug product processing

Pre-Clinical Studies

Completion of KRN-101 In-Process Quality Control and Toxicology studies ready for regulatory submissions

2022 — **Q2** — **Q3** — **Q4** — **2023** **Q1**

Partnerships/endorsements

Endorsement from National Cancer Research Institute and key oncology centres including the Christie in Manchester

Validated International Supply Chain

Successful import (EU) and export (CAN) of KRN API ready for pre-clinical studies

PK Study with iNGENu initiated

Site location, protocols, regulatory approach and personnel engaged

Operational Strategy

Timeline continued

KRN-101 ready for late-stage clinical trials and reimbursement negotiations

RWE Study - Safety & Efficacy

Randomized, double-blind, placebo-controlled, Phase 2b trial in patients with Cancer Related Distress

~200 participants

- 25mg
- 1mg (Active control)

2023

Q2

- ☐ **Open commercial IND for US Market**
  New Drug application for KRN-101's American expansion
- ☐ **KRN-101 PK Study First Patient First Visit**
  PK study begins with outputs expected within weeks. Results submitted to MHRA for RWE Study Sign off

Q3

- ☐ **PK Study Results**
  Clinical Study Report (CSR), publishing
- ☐ **RWE Study agreement with Manchester confirmed**
  Clinical Trial Application submitted, trial sites and patient pools identified

Q4

- ☐ **KRN-101 RWE Study First Patient First Visit**
  RWE study begins. Results submitted to MHRA for RWE Study Sign off

Commercial Strategy

Treatment Comparison & Revenue Assumptions

Indicative Annual Revenue for KRN-101 - £7,500/patient

Therapy	SSRI	Atypical antipsychotics	Cognitive Behavioral Therapy (CBT)	**KRN-101 & Therapy**	Spravato	Ketamine
Route	Oral	Oral	Therapy, Online/In Person	**Oral + Therapy**	Intranasal	Intravenous
Average Course of Treatment	Daily > 6 weeks	Daily > 6 weeks	10-20 Hours, ~4 months	**1 Dosing Session + 2-5 Therapy Sessions**	11 Sessions over >8 weeks Provided by a Doctor	Up to 9 Injections often with limited therapy
Reimbursement	Yes	Yes	Yes	**In development**	Yes (Not via NHS)	No
Estimated Treatment Cost £	1500	2,500-3,000	3,250	**7,500**	10,000	7,500
Estimated Annual Cost £*	13,000	22,000	6,500		25,000	16,000

19) Sertraline, 50mg/day, J Robinson 2021, 20)Citalopram, 150mg/day, 21)NHS cost of CBT via IAPT, NHS 2018, 22)Institute for Clinical and Economic Review 2019 23) L. Alison McInnes, 2021 *Based on usage over a year following recommended regimes for patients with refractory conditions

Early Revenue potential in the UK

Indicative Patient revenue: £7,500
Cost of goods: £1,500
Margin: 70-80%



The UK cancer related distress potential market for KRN is £7.5B

Revenues forecasted: 2024
Break-even point: 900-1,300 patients
(Projected for KRN-101 in the **UK market only**)



Increasing Value Throughout The Clinical Development Pathway

KRN-101 is currently going through preclinical validation, and the product will be used in a **Real World Evidence Study (P2b)**

Albert Labs expect to hit several critical value creation milestones

Case Study:

GW pharmaceuticals

Sold to Jazz Pharmaceuticals for $7.2bn May 2021 [26]

$500m	$2,000m	$4,000m
Value at the start of P2	Value at the start of P3	Value at Approval



24) J DiMasi et al., 2016 25) S Paul et al., 2010 26) Bay Bridge Bio, 2022

Psychedelic Comparables

Companies	Jurisdiction	Molecule	Indication	Stage	Valuation (CAD)*
Compass Pathways (NASDAQ: CMPS)	US	Psilocybin	Treatment Resistant Depression	Phase 2	482M
ATAI (NASDAQ: ATAI)	Germany	Arketamine, Ibogaine, & more	Neuropsychiatric Diseases, Opioid Addiction	Phase 2	390M
MindMed (NASDAQ: MNMD)	US	18-MC, LSD, NCE's	Opioid Addiction, Adult ADHD	Phase 1, Phase 2	141M
Cybin (NYSE: CYBN)	Canada	Psilocybin, NCE's	Major Depressive Disorder	Phase 2	136M
Small Pharma (TSXV:DMT)	**UK**	**DMT**	**Major Depressive Disorder**	**Phase 1/2**	**29M**
Albert Labs (CSE:ABRT)	**UK**	**KRN-101**	**Cancer-related Distress**	**Pre-clinical**	**5M**

**Values correct as of 11 January 2023*

Illustrated Potential of KRN-101

KRN-101 enters the UK Market			
	y+1	y+2	y+3
Proportion of **UK Market Cancer related anxiety**	0.02%	0.10%	0.50%
Recruited Patients	200	1,000	5,000
Revenue	2,359,200	11,796,000	117,960,000
Expenses	1,308,000	2,940,000	12,200,000
Total (CAD$)	**1,051,200**	**8,856,000**	**46,780,000**

Assumptions

Conservative/slow uptake of patients, based on the UK market and only cancer related distress patients

Treatment revenue from the analysis of other treatments in this area on Slide 22

Expenses include the cost of therapy, continued clinical operations & other overheads specific to KRN-101

*Please see forward looking statement on slide 35

To Summarise - Speed to Market, Revenue & Profit

1. Delivering safe & effective medicines to the **huge mental health market**

2. **Fast & early approval** with expansion into new and larger markets

3. A differentiated strategy using **RWE to accelerate medical authorisation**

4. **Experienced team** that can successfully bring new medicines to market

5. **A risk mitigated, low cost & validated strategy** allowing patients to get treatments they need now

Contact Us

Fully-integrated biopharmaceutical company,
bringing innovative prescription medicines to patients
with unmet mental health needs

For further information contact:

Email: info@albertlabs.com
Website: https://albertlabs.com/
Canada: +1 778-819-0740
United Kingdom: +44 1625 324 960

Appendix

Fully-integrated biopharmaceutical company, bringing innovative prescription medicines to patients with unmet mental health needs

Recent Press (1)

NOV 23, 2022, 08:30 ET
Albert Labs Announces Private Placement
Read more

NOV 17, 2022, 08:30 ET
Letter Of Intent (LOI) For First-In-Human Studies With INGENū CRO
Read more

OCT 25, 2022, 08:30 ET
Albert Labs Provides Corporate Update
Read more

OCT 20, 2022, 08:30 ET
New International PCT Patent Application For Scalable API Manufacturing
Read more

JUL 11, 2022, 08:30 ET
Albert Labs Appoints Two Industry Leading Directors
Read more

MAY 26, 2022, 08:30 ET
Albert Labs Appoints Principal Investigator for Real World Evidence Study for KRN-101
Read more

MAY 16, 2022, 08:30 ET
Albert Labs Granted Health Canada Licence
Read more

MAY 12, 2022, 08:30 ET
Albert Labs' Pre-Clinical Analytical and Toxicological Research Supports Company's Forthcoming Studies
Read more

Recent Press (2)

APR 26, 2022, 08:30 ET

Albert Labs Announces the Addition of Two Renowned Scientific Advisors SAB

Read more

MAR 30, 2022, 08:30 ET

Albert Labs Files US Provisional Patent Application and Proves Out Consistent and Rapidly Scalable Production of Psilocybe and Other Mycelia

Read more

MAR 10, 2022, 08:30 ET

Albert Labs (CSE:ABRT) Closes $4.7m Private Placement; Begins Trading on the Canadian Securities Exchange

Read more

JAN 04, 2022, 08:30 ET

MHRA Guidance on the use of Real-World Data in Clinical Studies for Regulatory Decision-Making Supports Albert Labs' Licensing Pathway

Read more

NOV 29, 2021, 08:30 ET

Albert Labs (CSE: ABRT) Receive Conditional Approval for CSE Listing & Appoint Chrystal Capital Partners to Advise on European Listing

Read more

JUN 24, 2021, 08:30 ET

Albert Labs Announces a Distinguished Clinical and Scientific Advisory Board

Read more

Appendix

Disclaimer

This document is a presentation (the “Presentation”) concerning certain general background information about the activities undertaken by Albert Labs Inc. (the “Company”) current as of March 29, 2021, unless stated otherwise. It is information in a summary form and does not purport to be complete. It is not intended to be relied upon as advice to investors or potential investors and does not take into account the investment objectives, financial situation or needs of any particular investor. These should be considered, with or without professional advice, when deciding if an investment is appropriate.

This Presentation does not constitute or form part of any offer for sale or solicitation of any offer to buy or subscribe for securities nor shall it or any part of it form the basis of or be relied on in connection with, or act as any inducement to enter into, any contract or commitment whatsoever. Recipients of this Presentation who are considering acquiring securities of the Company are reminded that any such purchase or subscription must not be made on the basis of the information contained in this Presentation but are referred to the entire body of publicly disclosed information regarding the Company, the entirety of any agreements, term sheets and other disclosure which is provided in connection with any such acquisition of securities, and any other information being furnished to the investor.

Each prospective purchaser of securities is reminded that the Company is a corporate entity situated in the Province of British Columbia, a jurisdiction that may have substantially different laws applicable to them than laws in the prospective investor’s own jurisdiction. Significant risk factors including those listed under the heading Forward-Looking Information and many more may affect the Company and its operations. As such, each acquisition of securities contains an inherently high degree of risk and the prospective purchaser should be ready to bear the loss of their entire investment.

In addition, these risks, uncertainties, assumptions and other factors could cause the Company’s actual results, performances, achievements and experience to differ materially from the Company’s expectations, future results, performances or achievements expressed or implied by the forward-looking statements. The forward-looking statements contained herein are presented for the purpose of assisting readers in understanding the Company’s expected financial and operating performance and the Company’s plans and objectives, and may not be appropriate for other purposes. You should read this information with the understanding that the Company’s actual future results may be materially different from what it expects. These forward-looking statements are expressly qualified in their entirety by this cautionary statement. The Company disclaim any obligation to update forward-looking statements, except as required by law.

The information contained in this Presentation is derived solely from management of the Company and otherwise publicly available information concerning the Company and does not purport to be all-inclusive or to contain all the information that an investor may desire to have in evaluating whether or not to make an investment in the Company. The information has not been independently verified and is subject to material updating, revision and further amendment, and is qualified entirely by reference to the Company’s publicly disclosed information and/or any other legal disclosure document(s). No representation or warranty, express or implied, is made or given by or on behalf of the Company, or any of its affiliates, directors, officers or employees as to the accuracy, completeness or fairness of the information or opinions contained in this Presentation and no responsibility or liability is accepted by any person for such information or opinions. The Company does not undertake or agree to update this Presentation or to correct any inaccuracies in, or omissions from, this Presentation that may become apparent. No person has been authorized to give any information or make any representations other than those contained in this Presentation and, if given and/or made, such information or representations must not be relied upon as having been so authorized. The information and opinions contained in this Presentation are provided as at the date of this Presentation. The contents of this Presentation are not to be construed as legal, financial or tax advice. Each prospective investor should contact his, her or its own legal adviser, independent financial adviser or tax adviser for legal, financial or tax advice.

Appendix

Forward-Looking Information (1)

This Presentation contains “forward-looking information” within the meaning of applicable Canadian securities laws and (“forward-looking statements”). Forward-looking statements in this Presentation include, but are not limited to, statements with respect to: the Company’s business plan and strategy, development and commercialization plans and objectives, business performance an, prospects and opportunities available to the Company, values and other economic indicators and estimations. Often but not always, forward-looking statements can be identified by the use of words such as “anticipate”, “outlook”, “envisage”, “believe”, “expect”, “project”, “estimate”, “likely”, “intend”, “should”, “could”, “may”, “might”, “target”, “plan” and other similar expressions or variations (including negative variations) of such words and phrases. Forward-looking statements are based on certain material assumptions and analysis made by the Company, and the opinions and estimates of management as of the date such statements are made and they represent management’s best judgment based on facts and assumptions that management considers reasonable in light of its experience and perception of historical trends, current conditions and expected future developments and other factors it believes are appropriate, and are subject to risks and uncertainties.

The material assumptions upon which forward-looking statements in this Presentation are based include, among others, assumptions with respect to: commercialization, growth plans and cash flows; the completion of target acquisitions; the demand for the Company’s services and products; future demand and trends in industries in which the Company may participate; the Company’s ability to achieve expected synergies cost savings and revenue; the Company’s ability to access financing on favorable terms from time to time; the Company’s ability to protect its intellectual property rights and that the Company will not infringe upon the intellectual property rights of others; the Company’s ability to source products at a reasonable cost; the Company’s ability to attract and retain customers; the continuation of executive and operating management or the non-disruptive replacement of them on competitive terms; the regulatory environment in which the Company operation; and stable market and general economic conditions; however, this data is inherently imprecise. The Company makes no representation that reasonable business people in possession of the same information would reach the same conclusions. Although the Company believes that the assumptions underlying forward-looking statements are reasonable, they may prove to be incorrect and the Company cannot assure that actual results will be consistent with such statements. Given these risks, uncertainties and assumptions, you should not place undue reliance on these forward-looking statements or the information contained in such statements.

Whether actual results, performance or achievements will conform to the Company’s expectations and predictions is subject to a number of known and unknown risks, uncertainties, assumptions and other factors, including the Company’s potential requirement for additional funding to develop its business and its ability to acquire such funding on commercially acceptable terms; and risks relating to the following: failure to complete target acquisitions on the expected terms or at all; liabilities associated with acquired companies or assets; failure to achieve expected synergies, cost savings, sales, revenue and / or EBITDA; the Company’s failure to economically commercialize its services; failure to protect the Company’s intellectual property rights; changes to the regulatory environment in which the Company operate and/or may operate; litigation or regulatory action; the ability of the Company to obtain appropriate insurance on commercially reasonable terms; the ability of the Company to maintain all licenses and permits necessary for the Company to carry out its businesses; delays or other problems in sourcing products; the Company’s inability to maintain or improve its competitive position; future demand and trends in sales failing to meet the Company’s expectations; the Company’s failure to retain key personnel and hire additional personnel needed to develop its business; the Company’s failure to adequately evaluate its current business and future prospects; foreign conversion rates; changes to applicable laws of any jurisdiction in which the Company’s operate or proposes to operate; and the Company’s business practice reputation being negatively affected by customer or user complaints or negative publicity. These risks, uncertainties, assumptions and other factors could cause the Company’s actual results, performances, achievements and experience to differ materially from the Company’s expectations, future results, performances or achievements expressed or implied by the forward-looking statements. The forward-looking statements contained herein are presented for the purpose of assisting readers in understanding the Company’s expected financial and operating performance and the Company’s plans and objectives, and may not be appropriate for other purposes. You should read this information with the understanding that the Company’s actual future results may be materially different from what it expects. These forward-looking statements are expressly qualified in their entirety by this cautionary statement. The Company disclaim any obligation to update forward-looking statements, except as required by law.

Appendix

Forward-Looking Information (2)

Statutory Rights Of Action
This Presentation may be considered an offering memorandum thereby granting the potential purchasers statutory rights and contractual rights of action. Securities legislation in certain provinces of Canada may provide a purchaser with remedies for rescission or damages if an offering memorandum (including any amendment thereto) contains a misrepresentation, provided that the remedies for rescission or damages are exercised by the purchaser within the time limit prescribed by the securities legislation of the purchaser's province. The purchaser should refer to any applicable provisions of the securities legislation of the purchaser's province or territory for particulars of these rights or consult with a legal advisor. For a brief summary, please see "Statutory Rights of Action" on page 27 of this presentation.

Additional Cautionary Language
This Presentation is strictly confidential and may not be reproduced, further distributed or published in whole or in part by any other person. Neither this Presentation nor any copy of it may be taken or transmitted into or distributed in any other jurisdiction which prohibits the same except in compliance with applicable laws. Any failure to comply with this restriction may constitute a violation of applicable securities law. Recipients are required to inform themselves of, and comply with, all such restrictions or prohibitions and the Company do not accept liability to any person in relation thereto.

The information contained in this Presentation does not purport to be all-inclusive or to contain all information that prospective investors may require. Prospective investors are encouraged to conduct their own analysis and reviews of the Company and of the information contained in this Presentation. The Company currently operates in a highly competitive and highly regulated market landscape. There can be no guarantee that the Company will achieve any of its intended targets.

An investor is not entitled to rely on parts of the information contained in this Presentation. The Company have not authorized anyone to provide investors with additional or different information. If anyone provides an investor with additional or different or inconsistent information, including statements in media articles about the Company, the investor should not rely on it. This document may only be used where it is legal to sell the securities proposed to be sold by the Company.

Appendix

Statutory Rights Of Action (1)

Securities legislation in certain provinces in Canada provides certain purchasers of securities pursuant to an offering memorandum with a right of action for damages or rescission, in addition to any other rights they may have at law, where the offering memorandum contains a "misrepresentation", as defined in the applicable securities legislation. A "misrepresentation" is generally an untrue statement of a material fact or an omission to state a material fact that is required to be stated or that is necessary to make any statement not misleading in light of the circumstances in which it was made. A "material fact" is a fact that would reasonably be expected to significantly affect the market price or value of the securities.

An "offering memorandum" generally means a document, together with any amendments to that document, purporting to describe the business and affairs of an issuer that has been prepared primarily for delivery to and review by a prospective purchaser so as to assist the prospective purchaser to make an investment decision in respect of securities being sold pursuant to an exemption from the requirement to prepare and file a prospectus contained in applicable securities law, but does not include a document setting out current information about an issuer for the benefit of a prospective purchaser familiar with the issuer through prior investment or business contacts. These rights, or notice with respect thereto, must be exercised or delivered by the purchaser within the time limits prescribed by applicable securities legislation. Each purchaser should refer to the complete text of the relevant provisions of the applicable securities legislation for the particulars of these rights or consult with a legal advisor. The rights of action for rescission or damages described herein are in addition to and without derogation from any other right or remedy that a purchaser may have at law. Set out below are descriptions outlining the rights of action available to purchasers resident in Ontario, Saskatchewan, New Brunswick, Nova Scotia and Newfoundland and Labrador which are required to be disclosed and are subject to the express provisions of the securities legislation of the applicable jurisdiction.

Rights for Purchasers in Ontario

Under Ontario securities legislation, a purchaser resident in Ontario who purchases securities offered by an offering memorandum during the period of distribution will have, subject to certain limitations and statutory defences, a statutory right of action for damages or, while still the owner of the securities, for rescission against the issuer in the event that the offering memorandum contains a misrepresentation, without regard to whether the purchaser relied on the misrepresentation. The right of action for damages is exercisable not later than the earlier of 180 days from the date the purchaser first has knowledge of the facts giving rise to the cause of action and three years from the date on which payment is made for the securities. The right of action for rescission is exercisable not later than 180 days from the date on which payment is made for the securities. If a purchaser elects to exercise the right of action for rescission, the purchaser will have no right of action for damages. In no case will the amount recoverable in any action exceed the price at which the securities were offered to the purchaser and if the purchaser is shown to have purchased the securities with knowledge of the misrepresentation, no person will be liable. In the case of an action for damages, the issuer will not be liable for all or any portion of the damages that are proven to not represent the depreciation in value of the securities as a result of the misrepresentation relied upon and in no case will the amount recoverable in any action exceed the price at which the securities were offered under the offering memorandum.